Navigation Links
Verenium Reports Financial Results for the Third Quarter 2010
Date:11/9/2010

act of manufacturing constraints compared to the prior year, resulting from the challenges of satisfying increased demand for our products and expanded product mix.

Operating Expenses (excluding cost of product revenue)

Excluding cost of product revenues, total operating expenses related to continuing operations decreased $4.3 million to $25.1 million (including share-based compensation of $0.8 million) for the nine months ended September 30, 2010 from $29.4 million (including share-based compensation of $3.9 million) for the same period in the prior year.  Excluding the impact of share-based compensation, total operating expenses decreased $1.2 million primarily due to $2.1 million of debt issuance costs during the third quarter of 2009 related to our 2007 Notes exchange and 2008 Notes amendment, partially offset by $1.4 million in bonus payments expensed during the third quarter of 2010.

Net Loss from Continuing Operations

Net loss from continuing operations for the nine months ended September 30, 2010 was $11.9 million compared to a net loss of $5.7 million for the same period in 2009, on a GAAP accounting basis. Adjusted for the non-cash impact of the tax benefit from income from discontinued operations, gains on debt extinguishment and amendments, and gains and losses for fair value remeasurements related to the 8% and 9% convertible notes, the Company's non-GAAP pro-forma net loss from continuing operations for the nine months ended September 30, 2010 was $16 million compared to $23.4 million for the same period in the prior year. The Company believes that excluding the impact of these items provides a more consistent measure of operating results.  

Net Income (Loss) from Discontinued Operations

For the nine months ended September 30, 2010, net income from discontinued operations was $9.8 million and included a $46.9 million gain on sale of the cellulosic biofuels business (net of tax p
'/>"/>

SOURCE Verenium Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Verenium to Present at Jefferies 10th Global Clean Technology Conference
2. Verenium and Alfa Laval Announce Extension of Purifine® PLC Enzyme Agreement
3. Verenium Announces Regulatory Approval for Purifine® PLC in China
4. Verenium Launches DELTAZYM® GA L-E5 Enzyme for Fuel Ethanol Production
5. Verenium Appoints Kevin Bracken Vice President of Manufacturing
6. Verenium Announces Proposed Public Offering of Common Stock
7. Verenium 1:12 Reverse Stock Split Takes Effect
8. Verenium Announces Reverse Stock Split to Take Effect September 9
9. BP and Verenium Announce Vercipia Biofuels to Advance the Commercialization of Cellulosic Ethanol
10. Verenium Completes Amendment to 8% Senior Convertible Notes
11. Verenium Announces Organizational Changes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... CAMBRIDGE, Mass. , Jan. 22, 2015   GenoSpace , ... suite of tools to enable the broad use of genomic, ... today announced the appointment of Michelle Munson , CEO ... independent director. Logo - http://photos.prnewswire.com/prnh/20150122/170713 ...
(Date:12/24/2014)... 24, 2014  United Therapeutics Corporation (NASDAQ: UTHR ... MDT ) has submitted a pre-market approval application to ... use of Medtronic,s SynchroMed ® II implantable drug ... with United Therapeutics, Remodulin ® (treprostinil) Injection delivered ...
(Date:12/24/2014)... 24, 2014   BioLife Solutions , Inc. (NASDAQ: ... clinical grade hypothermic storage and cryopreservation freeze ... cells and tissues  ("BioLife" or the "Company"), today announced that ... May 4, 2015 (the "Annual Meeting"). Because the ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 Earlier this year ... Sherley, director of the Adult Stem Cell Technology Center, LLC ... under appreciated unique property of adult tissue stem cells. ... the Past, Important for the Future,” embodied the essence of ...
Breaking Biology Technology:GenoSpace Expands Board with Appointment of Michelle Munson 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4BioLife Solutions Sets Date for Annual Meeting of Stockholders 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4
... Sept. 12 Prolog Ventures, a venture capital,firm ... Dan,Broderick has joined the firm as its fourth ... in early-stage investing, venture fund,management, and technology commercialization. ... managing director at Mason,Wells in Milwaukee, WI, where ...
... Scheduled for London, Paris, Munich, San ... Francisco, CA ... Scientific,part of The Thomson Corporation (NYSE: TOC ; ... worldwide research and business,communities, announced today that it will ...
... ... Artery Bypass Surgery, REDWOOD CITY, Calif., Sept. 12 ... received European CE Mark,(Conformite Europeenne) approval for the C-Port(R) Flex A ... C-Port(R) xA,Distal Anastomosis System product line and further facilitates the,automated anastomosis, ...
Cached Biology Technology:Dan Broderick Joins Prolog Ventures as Partner 2Dan Broderick Joins Prolog Ventures as Partner 3Thomson Scientific to Host Pharmaceutical Vision - A User's Conference for Information, Regulatory Affairs, Competitive Intelligence and Biotechnology Professionals 2Cardica Receives European CE Mark for C-Port Flex A System for Use in Coronary Artery Bypass Surgery 2Cardica Receives European CE Mark for C-Port Flex A System for Use in Coronary Artery Bypass Surgery 3
(Date:1/22/2015)... , Jan. 22, 2015   EyeLock, Inc. , a market ... appointed Steve Gerber to the new role of ... responsible for leading development of mobile platforms and wearable solutions ... success and innovation in the semiconductor industry to his role ...
(Date:12/22/2014)... Holiday Season may be the brightest ever for the ... long anticipated floodgates for consumer biometrics may finally be ... tablets, and wearable mobile devices that incorporate biometrics will ... nearly 4.8 billion biometric devices by 2020.   ...
(Date:12/17/2014)... Dec. 15, 2014 Research and Markets ( ... "Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor ... http://photos.prnewswire.com/prnh/20130307/600769 Based on ... Samsung introduces for the first time a fingerprint sensor ...
Breaking Biology News(10 mins):EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 2First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2
... the brain plays a key role in glucose regulation and the ... issue of the journal Nature . If the hypothesis is ... prevent and treat this disease, which is projected to affect one ... the paper, lead author Dr. Michael W. Schwartz, director of the ...
... Reusing the major greenhouse gas carbon dioxide (CO2) from industrial ... environment is on the verge of becoming a commercial ... in the U.S. are leading the way, according to an ... newsmagazine of the American Chemical Society. Alex Scott, C&EN,s ...
... be a key to early identification of autism, according to ... (NIMH), part of the National Institutes of Health. Published this ... the earliest sign of developing autism ever observeda steady decline ... six months of life. "Autism isn,t usually diagnosed ...
Cached Biology News:Brain may play key role in blood sugar metabolism and development of diabetes 2Earliest marker for autism found in young infants 2Earliest marker for autism found in young infants 3
...
... PS10 ProteinChip Arrays are preactivated with ... free primary amine groups. The PS10 array ... former PS1 array, but with an updated ... spot chips with 2 mm diameter spots ...
...
... ( Abpromise for all tested ... Synthetic peptide: IGPEVPDDRDFEPS conjugated to KLH, ... Human Decorin (fragment 36-49 of the ... Entrez GeneID: 1634 ...
Biology Products: